Roland Walter
Fred Hutch/University of Washington Cancer Consortium · Fred Hutchinson Cancer Center · Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
12
all conditions, ClinicalTrials.gov
NIH grants tied to them
14
1 more share only the name and are not shown
Trial papers in acute myeloid leukemia
43
PubMed author-name match
Trials
Studies that name Roland Walter as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:30 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04195945 · CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit PatientsFred Hutchinson Cancer Center · completed · Acute Myeloid Leukemia, Myeloid Neoplasm · principal investigator
- Ph1/Ph2NCT03531918 · Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid NeoplasmFred Hutchinson Cancer Center · completed · Acute Myeloid Leukemia · principal investigator
- Ph1/Ph2NCT02921061 · Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDSFred Hutchinson Cancer Center · completed · Mixed Phenotype Acute Leukemia, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia · principal investigator
- Ph1/Ph2NCT02044796 · Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromesFred Hutchinson Cancer Center · completed · Acute Biphenotypic Leukemia, de Novo Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome · principal investigator
- N/ANCT01804101 · Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid LeukemiaFred Hutchinson Cancer Center · completed · Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome · principal investigator
- N/ANCT01575535 · S0106B Studying Bone Marrow Samples From Women With Acute Myeloid LeukemiaSWOG Cancer Research Network · completed · Leukemia · principal investigator
- Ph1/Ph2NCT01342887 · Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaFred Hutchinson Cancer Center · terminated · Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a) · principal investigator
- Ph2NCT01235572 · Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive ChemotherapyFred Hutchinson Cancer Center · completed · Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a) · principal investigator
- N/ANCT01232842 · Biomarker Study in Tissue Samples From Patients With Acute Myeloid LeukemiaChildren's Oncology Group · completed · Leukemia · principal investigator
- Ph1/Ph2NCT00895934 · Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AMLNational Cancer Institute (NCI) · completed · Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a) · principal investigator
- N/ANCT00844441 · Early Discharge and Outpatient Care After Chemotherapy in Patients With Myelodysplastic Syndrome or Acute Myeloid LeukemiaFred Hutchinson Cancer Center · completed · Leukemia, Myelodysplastic Syndromes · principal investigator
- Ph2NCT00673153 · Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaFred Hutchinson Cancer Center · terminated · Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a) · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:30 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Base-Edited Hematopoietic Stem and Progenitor Cells To Enable Safe Use Of Highly Potent CD33-Targeted RadioimmunotherapyR01CA266556 · NCI · FRED HUTCHINSON CANCER CENTER · fiscal years 2022 to 2026 · $790,449 awarded in 2026Same name and institution; not confirmed by an ID
- Novel Approaches to CD33-Directed RadioimmunotherapyR37CA240832 · NCI · FRED HUTCHINSON CANCER CENTER · fiscal years 2020 to 2026 · $618,999 awarded in 2026Same name and institution; not confirmed by an ID
- Optimizing CD45-Targeted Astatine-211-Radioimmunotherapy for Malignant and Non-Malignant Blood DisordersR01CA303804 · NCI · FRED HUTCHINSON CANCER CENTER · fiscal years 2026 · $716,319 awarded in 2026Same name and institution; not confirmed by an ID
- Preventing Relapse After Non-myeloablative Stem Cell Transplantation: The Final ChallengeP01CA078902 · NCI · FRED HUTCHINSON CANCER CENTER · fiscal years 2025 · $2,074,913 awarded in 2025Same name and institution; not confirmed by an ID
- CD117-Targeted Radioimmunotherapy with Astatine-211 for Acute Myeloid Leukemia and Myelodysplastic SyndromeR21CA245598 · NCI · FRED HUTCHINSON CANCER CENTER · fiscal years 2022 to 2023 · $236,878 awarded in 2023Same name and institution; not confirmed by an ID
- Development of 211Astatine-Conjugated Anti-CD45 Antibody-Based Conditioning for Hematopoietic Stem Cell Gene Therapy and EditingR01HL151765 · NHLBI · FRED HUTCHINSON CANCER CENTER · fiscal years 2020 to 2023 · $861,939 awarded in 2023Same name and institution; not confirmed by an ID
- Optimizing NK Cell-Engaging Bispecific Antibody Therapy Targeting CD33R21CA259779 · NCI · FRED HUTCHINSON CANCER CENTER · fiscal years 2021 to 2022 · $201,587 awarded in 2022Same name and institution; not confirmed by an ID
- CAR T-Cell Therapy Targeting the Membrane-Proximal C2-Set Domain of CD33 for Treatment of Acute Myeloid Leukemia and Other CD33-Expressing Hematopoietic NeoplasmsR21CA245594 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · fiscal years 2020 to 2021 · $157,326 awarded in 2021Same name and institution; not confirmed by an ID
- Optimization of Siglec-8-Directed Immunotherapy for Eosinophilic and Mast Cell DisordersR21AI150566 · NIAID · FRED HUTCHINSON CANCER CENTER · fiscal years 2020 to 2021 · $113,858 awarded in 2021Same name and institution; not confirmed by an ID
- Novel Approach to CD33-Targeted Immunotherapy of Acute Myeloid LeukemiaR21CA234203 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · fiscal years 2019 to 2020 · $184,296 awarded in 2020Same name and institution; not confirmed by an ID
- Treatment of Acute Myeloid Leukemia with C2-Set Domain-Specific CD33 AntibodiesR21CA223409 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · fiscal years 2018 to 2019 · $222,789 awarded in 2019Same name and institution; not confirmed by an ID
- Prediction of Treatment-Related Mortality and Therapeutic Resistance in AMLR21CA182010 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · fiscal years 2014 to 2015 · $195,938 awarded in 2015Same name and institution; not confirmed by an ID
- Prognostic and Functional Significance of Adhesion Molecules in Pediatric AMLR21CA161894 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · fiscal years 2012 to 2013 · $150,559 awarded in 2013Same name and institution; not confirmed by an ID
- AML Stem Cell Heterogeneity: Implications for Gemtuzumab Ozogomicin-based TherapyK23CA137161 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · fiscal years 2009 · $121,236 awarded in 2009Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Cancer Center AdministrationP30CA015704 · NCI · FRED HUTCHINSON CANCER CENTER · PI WENDY LAW · fiscal years 2018 to 2026
- U10CA032102RePORTER returned no project for this number; it is shown as the registry gives it.Named on NCT01575535
Most cited trial papers
Clinical-trial papers with this author name in acute myeloid leukemia, ranked by citations from NIH iCite, fetched 2026-11-12 10:30 UTC. The ranking covers the 200 most relevant of 43 PubMed records, and a shared surname and initials can bring in a namesake. All 43 on PubMed
- Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.J Clin Oncol · 2019568 citationsRCR 21.6
- 522 citationsRCR 13.9
- 281 citationsRCR 14.8
- 160 citationsRCR 5.3
- 136 citationsRCR 3.8
- 129 citationsRCR 3.8
- Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial.Lancet Oncol · 2024117 citationsRCR 14.5
- 100 citationsRCR 2.5
- Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia.Clin Cancer Res · 201679 citationsRCR 2.4
- 77 citationsRCR 1.9